Blog

A new interesting article has been published in Virchows Arch. 2019 Jul;475(1):95-104. doi: 10.1007/s00428-019-02550-8. Epub 2019 Mar 22. and titled:

Robust expression of EZH2 in endocervical neoplastic lesions.

Authors of this article are:

Makk E, Bálint L, Cifra J, Tornóczky T, Oszter A, Tóth A, Kálmán E, Kovács K.

A summary of the article is shown below:

The aim of this study was to evaluate the nuclear expression of histone methyltransferase enhancer of zeste homolog 2 (EZH2) in endocervical neoplastic lesions such as invasive endocervical adenocarcinoma (ECA) and cervical in situ adenocarcinoma (AIS) in comparison with normal endocervix and non-neoplastic counterparts. A total of 54 consecutive neoplastic cases (37 ECA, 17 AIS) and 32 non-neoplastic endocervical lesions (15 reactive atypia, 9 microglandular hyperplasia, 3 tuboendometrioid metaplasia, 3 tunnel cluster, 2 endometriosis) were included in the study with adjacent normal endocervix if present. EZH2 immunoreactivity was evaluated semiquantitatively by three independent experts in lesions and adjacent normal glandular epithelium as well. EZH2 expression was defined robust if at least two of the three experts rated partial or diffuse positivity. Robust EZH2 expression was statistically compared among the neoplastic, non-neoplastic, and normal glandular epithelium samples. Diagnostic test capability of robust EZH2 expression was calculated. Fifty-three out of the 54 neoplastic cases (98%) showed robust EZH2 expression. Robust EZH2 expression was significantly less often (4 out of 32 cases, 12.5%) found in the non-neoplastic endocervical lesions (p < 0.0001) and never (0 out of 66 samples) in the adjacent normal glandular epithelium. Robust EZH2 overexpression had a sensitivity and specificity of over 95% in detecting neoplastic lesions versus non-neoplastic lesions or normal glandular epithelium. EZH2 may play a role in the pathogenesis of endocervical neoplasia, and the detection of robust expression of EZH2 might be a useful differential diagnostic tool in problematic endocervical lesions in histology and cytology as well.
Check out the article’s website on Pubmed for more information:

[link-preview url=https://www.ncbi.nlm.nih.gov/pubmed/30903272 forceshot=true]

This article is a good source of information and a good way to become familiar with topics such as: Adenocarcinoma;Adenocarcinoma in Situ;Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Cell Nucleus;Cervical Intraepithelial Neoplasia;Enhancer of Zeste Homolog 2 Protein;Female;Humans;Immunohistochemistry;Middle Aged;Predictive Value of Tests;Uterine Cervical Neoplasms.

New Chemicals from MOLECULAR DEPOT

New Proteins from MOLECULAR DEPOT


New Antibodies from MOLECULAR DEPOT


New Research Kits from MOLECULAR DEPOT